JP2007502807A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007502807A5 JP2007502807A5 JP2006523695A JP2006523695A JP2007502807A5 JP 2007502807 A5 JP2007502807 A5 JP 2007502807A5 JP 2006523695 A JP2006523695 A JP 2006523695A JP 2006523695 A JP2006523695 A JP 2006523695A JP 2007502807 A5 JP2007502807 A5 JP 2007502807A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- quinazolin
- yloxy
- pyridin
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000003112 inhibitor Substances 0.000 claims 27
- 239000008194 pharmaceutical composition Substances 0.000 claims 17
- 125000000623 heterocyclic group Chemical group 0.000 claims 14
- -1 C 1 -C 6 alkoxy Chemical group 0.000 claims 11
- 125000003118 aryl group Chemical group 0.000 claims 10
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 8
- 101710100968 Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 8
- 125000005843 halogen group Chemical group 0.000 claims 7
- 125000004430 oxygen atom Chemical group O* 0.000 claims 7
- 229910052799 carbon Inorganic materials 0.000 claims 5
- 125000004432 carbon atom Chemical group C* 0.000 claims 5
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 5
- 125000001424 substituent group Chemical group 0.000 claims 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 125000004434 sulfur atom Chemical group 0.000 claims 4
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 4
- DKGVTDKLGNLAPO-UHFFFAOYSA-N 2-(hydroxymethyl)-n-[3-[4-[3-methyl-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]prop-2-ynyl]pyrrolidine-1-carboxamide Chemical compound C1=NC(C)=CC=C1OC(C(=C1)C)=CC=C1NC1=NC=NC2=CC=C(C#CCNC(=O)N3C(CCC3)CO)C=C12 DKGVTDKLGNLAPO-UHFFFAOYSA-N 0.000 claims 3
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 3
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- OURYUHOHOFWENB-UHFFFAOYSA-N n-(3-methyl-4-pyridin-3-yloxyphenyl)-6-(2-piperidin-3-ylethynyl)quinazolin-4-amine Chemical compound C=1C=C(OC=2C=NC=CC=2)C(C)=CC=1NC(C1=C2)=NC=NC1=CC=C2C#CC1CCCNC1 OURYUHOHOFWENB-UHFFFAOYSA-N 0.000 claims 3
- NRZMNEKBNBVFSJ-UHFFFAOYSA-N n-[3-methyl-4-(6-methylpyridin-3-yl)oxyphenyl]-6-(2-piperidin-3-ylethynyl)quinazolin-4-amine Chemical compound C1=NC(C)=CC=C1OC(C(=C1)C)=CC=C1NC1=NC=NC2=CC=C(C#CC3CNCCC3)C=C12 NRZMNEKBNBVFSJ-UHFFFAOYSA-N 0.000 claims 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 239000000651 prodrug Substances 0.000 claims 3
- 229940002612 prodrug Drugs 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 3
- 239000012453 solvate Substances 0.000 claims 3
- LLVZBTWPGQVVLW-SNAWJCMRSA-N CP-724714 Chemical compound C12=CC(/C=C/CNC(=O)COC)=CC=C2N=CN=C1NC(C=C1C)=CC=C1OC1=CC=C(C)N=C1 LLVZBTWPGQVVLW-SNAWJCMRSA-N 0.000 claims 2
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 230000002159 abnormal effect Effects 0.000 claims 2
- 230000010261 cell growth Effects 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 229960002584 gefitinib Drugs 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims 2
- 229960002930 sirolimus Drugs 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 229960005486 vaccine Drugs 0.000 claims 2
- MIIQJAUWHSUTIT-UHFFFAOYSA-N 1,2-oxazole-5-carboxylic acid Chemical compound OC(=O)C1=CC=NO1 MIIQJAUWHSUTIT-UHFFFAOYSA-N 0.000 claims 1
- CXSODTANAUJQKJ-UHFFFAOYSA-N 1-ethyl-3-[2-methyl-4-[4-[3-methyl-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]but-3-yn-2-yl]urea Chemical compound C12=CC(C#CC(C)(C)NC(=O)NCC)=CC=C2N=CN=C1NC(C=C1C)=CC=C1OC1=CC=C(C)N=C1 CXSODTANAUJQKJ-UHFFFAOYSA-N 0.000 claims 1
- FIHRYOGQFRGJTM-UHFFFAOYSA-N 1-ethyl-3-[3-[4-[3-methyl-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]prop-2-ynyl]urea Chemical compound C12=CC(C#CCNC(=O)NCC)=CC=C2N=CN=C1NC(C=C1C)=CC=C1OC1=CC=C(C)N=C1 FIHRYOGQFRGJTM-UHFFFAOYSA-N 0.000 claims 1
- AFNJRWJHTHPHFY-UHFFFAOYSA-N 2-(dimethylamino)-n-[3-[4-(3-methyl-4-pyridin-3-yloxyanilino)quinazolin-6-yl]prop-2-ynyl]acetamide Chemical compound C12=CC(C#CCNC(=O)CN(C)C)=CC=C2N=CN=C1NC(C=C1C)=CC=C1OC1=CC=CN=C1 AFNJRWJHTHPHFY-UHFFFAOYSA-N 0.000 claims 1
- HKXJUPUXPYJGBC-UHFFFAOYSA-N 2-fluoro-n-[3-[4-[3-methyl-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]prop-2-ynyl]acetamide Chemical compound C1=NC(C)=CC=C1OC(C(=C1)C)=CC=C1NC1=NC=NC2=CC=C(C#CCNC(=O)CF)C=C12 HKXJUPUXPYJGBC-UHFFFAOYSA-N 0.000 claims 1
- ZYAJQMUTJUFTQJ-UHFFFAOYSA-N 2-methoxy-n-[1-[2-[4-[3-methyl-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]ethynyl]cyclopropyl]acetamide Chemical compound C=1C=C2N=CN=C(NC=3C=C(C)C(OC=4C=NC(C)=CC=4)=CC=3)C2=CC=1C#CC1(NC(=O)COC)CC1 ZYAJQMUTJUFTQJ-UHFFFAOYSA-N 0.000 claims 1
- QHRCOBHMIMIKJW-UHFFFAOYSA-N 2-methoxy-n-[3-[4-(3-methyl-4-pyridin-3-yloxyanilino)quinazolin-6-yl]prop-2-ynyl]acetamide Chemical compound C12=CC(C#CCNC(=O)COC)=CC=C2N=CN=C1NC(C=C1C)=CC=C1OC1=CC=CN=C1 QHRCOBHMIMIKJW-UHFFFAOYSA-N 0.000 claims 1
- ZTOIFVLFPSFAIL-UHFFFAOYSA-N 2-methoxy-n-[3-[4-[3-methyl-4-(2-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]prop-2-ynyl]acetamide Chemical compound C12=CC(C#CCNC(=O)COC)=CC=C2N=CN=C1NC(C=C1C)=CC=C1OC1=CC=CN=C1C ZTOIFVLFPSFAIL-UHFFFAOYSA-N 0.000 claims 1
- BAVGSGLGSGTNSC-UHFFFAOYSA-N 2-methoxy-n-[3-[4-[3-methyl-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]prop-2-ynyl]acetamide Chemical compound C12=CC(C#CCNC(=O)COC)=CC=C2N=CN=C1NC(C=C1C)=CC=C1OC1=CC=C(C)N=C1 BAVGSGLGSGTNSC-UHFFFAOYSA-N 0.000 claims 1
- OONFNUWBHFSNBT-HXUWFJFHSA-N AEE788 Chemical compound C1CN(CC)CCN1CC1=CC=C(C=2NC3=NC=NC(N[C@H](C)C=4C=CC=CC=4)=C3C=2)C=C1 OONFNUWBHFSNBT-HXUWFJFHSA-N 0.000 claims 1
- BUROJSBIWGDYCN-GAUTUEMISA-N AP 23573 Chemical compound C1C[C@@H](OP(C)(C)=O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 BUROJSBIWGDYCN-GAUTUEMISA-N 0.000 claims 1
- 101100123850 Caenorhabditis elegans her-1 gene Proteins 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims 1
- 229940029041 HER-2/neu vaccine Drugs 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims 1
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 150000001540 azides Chemical class 0.000 claims 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- 150000001721 carbon Chemical group 0.000 claims 1
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 claims 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 claims 1
- 229960005395 cetuximab Drugs 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 229960001433 erlotinib Drugs 0.000 claims 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims 1
- 229960005167 everolimus Drugs 0.000 claims 1
- 229940084651 iressa Drugs 0.000 claims 1
- 229940124302 mTOR inhibitor Drugs 0.000 claims 1
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims 1
- 229950008001 matuzumab Drugs 0.000 claims 1
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- ZTFBIUXIQYRUNT-MDWZMJQESA-N mubritinib Chemical compound C1=CC(C(F)(F)F)=CC=C1\C=C\C1=NC(COC=2C=CC(CCCCN3N=NC=C3)=CC=2)=CO1 ZTFBIUXIQYRUNT-MDWZMJQESA-N 0.000 claims 1
- NUXRNLPBHAIASC-UHFFFAOYSA-N n-(3-methyl-4-pyridin-3-yloxyphenyl)-6-(2-piperidin-4-ylethynyl)quinazolin-4-amine Chemical compound C=1C=C(OC=2C=NC=CC=2)C(C)=CC=1NC(C1=C2)=NC=NC1=CC=C2C#CC1CCNCC1 NUXRNLPBHAIASC-UHFFFAOYSA-N 0.000 claims 1
- PGNQYDWBJQHLKF-UHFFFAOYSA-N n-[3-[4-[3-chloro-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]prop-2-ynyl]acetamide Chemical compound C12=CC(C#CCNC(=O)C)=CC=C2N=CN=C1NC(C=C1Cl)=CC=C1OC1=CC=C(C)N=C1 PGNQYDWBJQHLKF-UHFFFAOYSA-N 0.000 claims 1
- IZXNOTSZIXTRGF-UHFFFAOYSA-N n-[3-[4-[3-methyl-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]prop-2-ynyl]acetamide Chemical compound C12=CC(C#CCNC(=O)C)=CC=C2N=CN=C1NC(C=C1C)=CC=C1OC1=CC=C(C)N=C1 IZXNOTSZIXTRGF-UHFFFAOYSA-N 0.000 claims 1
- WXSXUUGOBYKRSY-UHFFFAOYSA-N n-[3-[4-[3-methyl-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]prop-2-ynyl]piperazine-1-carboxamide Chemical compound C1=NC(C)=CC=C1OC(C(=C1)C)=CC=C1NC1=NC=NC2=CC=C(C#CCNC(=O)N3CCNCC3)C=C12 WXSXUUGOBYKRSY-UHFFFAOYSA-N 0.000 claims 1
- HJDLJTQZLYROKJ-UHFFFAOYSA-N n-[3-methyl-4-(2-methylpyridin-3-yl)oxyphenyl]-6-(2-piperidin-4-ylethynyl)quinazolin-4-amine Chemical compound C=1C=C(OC=2C(=NC=CC=2)C)C(C)=CC=1NC(C1=C2)=NC=NC1=CC=C2C#CC1CCNCC1 HJDLJTQZLYROKJ-UHFFFAOYSA-N 0.000 claims 1
- ZTNZMOQHMZZCBD-UHFFFAOYSA-N n-[3-methyl-4-(6-methylpyridin-3-yl)oxyphenyl]-6-(2-piperidin-4-ylethynyl)quinazolin-4-amine Chemical compound C1=NC(C)=CC=C1OC(C(=C1)C)=CC=C1NC1=NC=NC2=CC=C(C#CC3CCNCC3)C=C12 ZTNZMOQHMZZCBD-UHFFFAOYSA-N 0.000 claims 1
- 230000002018 overexpression Effects 0.000 claims 1
- 229960001972 panitumumab Drugs 0.000 claims 1
- WVUNYSQLFKLYNI-AATRIKPKSA-N pelitinib Chemical compound C=12C=C(NC(=O)\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC1=CC=C(F)C(Cl)=C1 WVUNYSQLFKLYNI-AATRIKPKSA-N 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 230000036470 plasma concentration Effects 0.000 claims 1
- 229940099538 rapamune Drugs 0.000 claims 1
- 229960001302 ridaforolimus Drugs 0.000 claims 1
- 150000003384 small molecules Chemical class 0.000 claims 1
- 230000002195 synergetic effect Effects 0.000 claims 1
- 229960000235 temsirolimus Drugs 0.000 claims 1
- 229960000575 trastuzumab Drugs 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49591903P | 2003-08-18 | 2003-08-18 | |
| PCT/IB2004/002580 WO2005016347A1 (en) | 2003-08-18 | 2004-08-06 | Dosing schedule for erbb2 anticancer agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007502807A JP2007502807A (ja) | 2007-02-15 |
| JP2007502807A5 true JP2007502807A5 (enExample) | 2007-09-20 |
Family
ID=34193358
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006523695A Withdrawn JP2007502807A (ja) | 2003-08-18 | 2004-08-06 | Ｅｒｂｂ２抗がん剤の投与スケジュール |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20050119288A1 (enExample) |
| EP (1) | EP1658080A1 (enExample) |
| JP (1) | JP2007502807A (enExample) |
| KR (2) | KR20060037447A (enExample) |
| CN (1) | CN1838959A (enExample) |
| AR (1) | AR045268A1 (enExample) |
| AU (1) | AU2004264726A1 (enExample) |
| BR (1) | BRPI0413745A (enExample) |
| CA (1) | CA2536140A1 (enExample) |
| CO (1) | CO5670356A2 (enExample) |
| IL (1) | IL173127A0 (enExample) |
| MX (1) | MXPA06001989A (enExample) |
| NO (1) | NO20061252L (enExample) |
| RU (1) | RU2328287C2 (enExample) |
| SG (1) | SG135193A1 (enExample) |
| TW (1) | TW200522966A (enExample) |
| WO (1) | WO2005016347A1 (enExample) |
| ZA (1) | ZA200600517B (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4547911B2 (ja) | 2002-02-01 | 2010-09-22 | アリアド・ファーマシューティカルズ・インコーポレイテッド | リン含有化合物およびその用途 |
| US8505468B2 (en) * | 2002-11-19 | 2013-08-13 | Sharp Kabushiki Kaisha | Substrate accommodating tray |
| KR101028952B1 (ko) | 2003-08-14 | 2011-04-12 | 어레이 바이오파마 인크. | 수용체 티로신 키나아제 억제제로서의 퀴나졸린 유사체 |
| US7501427B2 (en) | 2003-08-14 | 2009-03-10 | Array Biopharma, Inc. | Quinazoline analogs as receptor tyrosine kinase inhibitors |
| US8318752B2 (en) | 2003-09-19 | 2012-11-27 | Astrazeneca Ab | 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-{[1-(N-methylcarbamoyl-methyl)piperidin-4-yl]oxy}quinazoline, its pharmaceutically acceptable salts, and pharmaceutical compositions comprising the same |
| NZ550796A (en) | 2004-05-06 | 2010-07-30 | Warner Lambert Co | 4-phenylamino-quinazolin-6-yl-amides |
| GB0427131D0 (en) * | 2004-12-10 | 2005-01-12 | Glaxosmithkline Biolog Sa | Novel combination |
| JP2008542354A (ja) * | 2005-06-03 | 2008-11-27 | ファイザー・プロダクツ・インク | 癌治療におけるｅｒｂＢ２阻害剤と他の治療薬の併用 |
| AU2006259261B2 (en) * | 2005-06-16 | 2013-06-13 | Myrexis, Inc. | Pharmaceutical compositions and use thereof |
| WO2007014335A2 (en) * | 2005-07-27 | 2007-02-01 | The University Of Texas System | Combinations comprising gemcitabine and tyrosine kinase inhibitors for the treatment of pancreatic cancer |
| US8945573B2 (en) | 2005-09-08 | 2015-02-03 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Targeted identification of immunogenic peptides |
| AU2006315512B2 (en) * | 2005-11-14 | 2012-11-01 | Ariad Pharmaceuticals, Inc. | Administration of an mTOR inhibitor to treat patients with cancer |
| KR101086967B1 (ko) | 2005-11-15 | 2011-11-29 | 어레이 바이오파마 인크. | 과다증식성 질환의 치료를 위한 ｅｒｂｂ 유형 ｉ 수용체티로신 키나제 억제제로서의 ｎ4-페닐-퀴나졸린-4-아민유도체 및 관련 화합물 |
| EP2010911A4 (en) * | 2006-03-31 | 2009-05-13 | Massachusetts Inst Technology | TREATMENT OF EGF RECEPTOR MUTANTS EXPRESSING TUMORS |
| EP2004165A2 (en) * | 2006-04-05 | 2008-12-24 | Novartis Pharma AG | Synergistic combinations of anticancer agents for treating cancer |
| AU2007319825B2 (en) | 2006-11-14 | 2014-01-23 | Ariad Pharmaceuticals, Inc. | Oral formulations |
| AU2008236993A1 (en) * | 2007-04-10 | 2008-10-16 | Myrexis, Inc. | Method of treating brain cancer |
| CA2720989A1 (en) * | 2007-04-10 | 2008-10-16 | Myrexis, Inc. | Methods for treating cancer |
| AU2008236994A1 (en) * | 2007-04-10 | 2008-10-16 | Myrexis, Inc. | Method of treating melanoma |
| WO2008124824A1 (en) * | 2007-04-10 | 2008-10-16 | Myriad Genetics, Inc. | Dosages and methods for the treatment of cancer |
| WO2008124828A1 (en) * | 2007-04-10 | 2008-10-16 | Myriad Genetics, Inc. | Methods for treating vascular disruption disorders |
| ES2583377T3 (es) | 2007-06-08 | 2016-09-20 | Genentech, Inc. | Marcadores de expresión génica de la resistencia tumoral al tratamiento con inhibidor de HER2 |
| US9551033B2 (en) | 2007-06-08 | 2017-01-24 | Genentech, Inc. | Gene expression markers of tumor resistance to HER2 inhibitor treatment |
| US8252805B2 (en) * | 2008-05-07 | 2012-08-28 | Teva Pharmaceutical Industries Ltd. | Forms of lapatinib ditosylate and processes for preparation thereof |
| WO2010027848A2 (en) * | 2008-08-26 | 2010-03-11 | Teva Pharmaceutical Industries Ltd. | Forms of lapatinib compounds and processes for the preparation thereof |
| NZ594665A (en) | 2009-03-20 | 2013-08-30 | Genentech Inc | Bispecific anti-her antibodies |
| WO2013078440A2 (en) * | 2011-11-23 | 2013-05-30 | Intellikine, Llc | Enhanced treatment regimens using mtor inhibitors |
| CN110564604B (zh) * | 2014-01-31 | 2023-09-29 | 凸版印刷株式会社 | 液滴的形成方法、生物分子分析方法及生物分子分析试剂盒 |
| CN108473538B (zh) * | 2015-10-28 | 2022-01-28 | 塔弗达治疗有限公司 | Sstr靶向缀合物及其颗粒和制剂 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA932522B (en) * | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
| DE69522717T2 (de) * | 1995-03-30 | 2002-02-14 | Pfizer Inc., New York | Chinazolinderivate |
| GB9718972D0 (en) * | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| MXPA02012870A (es) * | 2000-06-22 | 2003-05-14 | Pfizer Prod Inc | Derivados biciclicos sustituidos para el tratamiento del crecimiento celular anormal. |
| WO2003049740A1 (en) * | 2001-12-12 | 2003-06-19 | Pfizer Products Inc. | Quinazoline derivatives for the treatment of abnormal cell growth |
| HRP20040530A2 (en) * | 2001-12-12 | 2004-10-31 | Pfizer Prod Inc | Salt forms of e-2-methoxy-n-(3-(4-(3-methyl-pyridin-3-yloxy)-phenylamino)-quinazolin-6-yl)-allyl)-acetamide, its preparation and its use against cancer |
| EP1567506A4 (en) * | 2002-11-20 | 2007-06-20 | Array Biopharma Inc | CYANOGUANIDINES AND CYANOAMIDINES AS INHIBITORS OF ERBB2 AND EGFR |
| AU2003303045A1 (en) * | 2002-12-18 | 2004-07-09 | Pfizer Products Inc. | 4-anilino quinazoline derivatives for the treatment of abnormal cell growth |
-
2004
- 2004-08-06 CA CA002536140A patent/CA2536140A1/en not_active Abandoned
- 2004-08-06 MX MXPA06001989A patent/MXPA06001989A/es not_active Application Discontinuation
- 2004-08-06 KR KR1020067003190A patent/KR20060037447A/ko not_active Ceased
- 2004-08-06 JP JP2006523695A patent/JP2007502807A/ja not_active Withdrawn
- 2004-08-06 BR BRPI0413745-0A patent/BRPI0413745A/pt not_active IP Right Cessation
- 2004-08-06 EP EP04744217A patent/EP1658080A1/en not_active Withdrawn
- 2004-08-06 CN CNA200480023705XA patent/CN1838959A/zh active Pending
- 2004-08-06 WO PCT/IB2004/002580 patent/WO2005016347A1/en not_active Ceased
- 2004-08-06 KR KR1020087000092A patent/KR20080014144A/ko not_active Withdrawn
- 2004-08-06 RU RU2006102125/14A patent/RU2328287C2/ru not_active IP Right Cessation
- 2004-08-06 SG SG200706063-5A patent/SG135193A1/en unknown
- 2004-08-06 AU AU2004264726A patent/AU2004264726A1/en not_active Abandoned
- 2004-08-17 TW TW093124706A patent/TW200522966A/zh unknown
- 2004-08-17 AR ARP040102941A patent/AR045268A1/es not_active Application Discontinuation
- 2004-08-17 US US10/919,831 patent/US20050119288A1/en not_active Abandoned
-
2006
- 2006-01-12 IL IL173127A patent/IL173127A0/en unknown
- 2006-01-18 ZA ZA200600517A patent/ZA200600517B/xx unknown
- 2006-02-15 CO CO06015089A patent/CO5670356A2/es not_active Application Discontinuation
- 2006-03-17 NO NO20061252A patent/NO20061252L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007502807A5 (enExample) | ||
| RU2006102125A (ru) | Схема приема erbb2 противоопухолевых агентов | |
| JP7187729B2 (ja) | Ｒｉｐ１阻害剤化合物並びにそれを製造及び使用するための方法 | |
| JP7108146B2 (ja) | 新規メチルキナゾリノン誘導体 | |
| US20220153737A1 (en) | Solid forms of a compound modulating kinases | |
| TW202146021A (zh) | 包含達拉菲尼、erk抑制劑和shp2抑制劑之三重藥物組合 | |
| US7999006B2 (en) | Methods of using MEK inhibitors | |
| IL295799A (en) | Trophomyosin receptor kinase (trk) degradation compounds and methods of use | |
| US8431585B2 (en) | Use of inhibitors of the EGFR-mediated signal transduction for the treatment of benign prostatic hyperplasia (BPH)/prostatic hypertrophy | |
| US20100234349A1 (en) | Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer | |
| EP2222166B1 (en) | Heterocyclic kinase inhibitors | |
| JP2011504497A5 (enExample) | ||
| RU2009136299A (ru) | Новые производные 3-({1,2,4}триазоло{4,3-а}пиридин-7-ил)бензамида | |
| US20130012465A1 (en) | Bibw 2992 for use in the treatment of triple negative breast cancer | |
| JP2005519083A5 (enExample) | ||
| JP2008509187A5 (enExample) | ||
| RU2007108861A (ru) | Трифтометилзамещенные бензамиды в качестве ингибиторов киназ | |
| JP2011521938A5 (enExample) | ||
| TNSN07018A1 (en) | New 4-benzylidene-piperidin derivatives | |
| CN112334132A (zh) | 用于治疗与神经纤维敏感化相关的疾病的1,3-噻唑-2-基取代的苯甲酰胺 | |
| JP2018090566A (ja) | 非小細胞肺癌の治療のためのｅｇｆｒ ｔ７９０ｍ阻害剤およびｃｄｋ阻害剤の組合せ | |
| US8318754B2 (en) | Pyrimidinecarboxamide derivatives | |
| JP2023506809A (ja) | Ｅｇｆｒ阻害剤 | |
| RU2009136246A (ru) | Новые соединения 707 и их применение | |
| JP2007509052A5 (enExample) |